[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535241":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":27,"responsibleParty":129,"collaborators":133,"id":137,"slug":10,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":138,"sex":143,"minAge":144,"maxAge":10,"enrollmentInfo":145,"targetDuration":148,"studyType":149,"phases":10,"briefSummary":150,"conditions":151,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"Nova Scotia Health Authority","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"RASTA AF Cohort",null,"Patients who meet the inclusion criteria for RASTA-AF, and do not meet any of the exclusion criteria but decline or are not approached for participation in the RCT will be asked to participate.",[13],{"name":14,"affiliation":15,"role":16},"Ratika Parkash, MD, FRCPC","Nova Scotia Health","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Laura Hamilton, BSC, MAHSR","CONTACT","902 473-7226","laura.hamilton@nshealth.ca",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},"Karen Giddens","902 237-5551","karen.giddens@nshealth.ca",[28,45,61,75,88,101,115],{"facility":29,"status":30,"city":31,"state":32,"zip":10,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Foothills Hospital","RECRUITING","Calgary","Alberta","Canada",{"type":35,"coordinates":36},"Point",[37,38],-114.08529,51.05011,{"lat":38,"lon":37},[41,43],{"name":42,"role":20,"phone":10,"phoneExt":10,"email":10},"Jennifer McKeage",{"name":44,"role":16,"phone":10,"phoneExt":10,"email":10},"Stephen Wilton, MD, FRCPC",{"facility":46,"status":30,"city":47,"state":48,"zip":49,"country":33,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"QEIIHSC","Halifax","Nova Scotia","B3H 3A7",{"type":35,"coordinates":51},[52,53],-63.57688,44.64269,{"lat":53,"lon":52},[56,60],{"name":57,"role":20,"phone":58,"phoneExt":10,"email":59},"Laura Hamilton","902-473-7226","laura.hamiton@nshealth.ca",{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"facility":62,"status":30,"city":63,"state":64,"zip":10,"country":33,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"London Health Sciences Centre","London","Ontario",{"type":35,"coordinates":66},[67,68],-81.23304,42.98339,{"lat":68,"lon":67},[71,73],{"name":72,"role":20,"phone":10,"phoneExt":10,"email":10},"Keza Motlana",{"name":74,"role":16,"phone":10,"phoneExt":10,"email":10},"Allan Skanes, MD, FRCP(C)",{"facility":76,"status":30,"city":77,"state":64,"zip":10,"country":33,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"University of Ottawa Heart Institute","Ottawa",{"type":35,"coordinates":79},[80,81],-75.69812,45.41117,{"lat":81,"lon":80},[84,86],{"name":85,"role":20,"phone":10,"phoneExt":10,"email":10},"Tammy Knight",{"name":87,"role":16,"phone":10,"phoneExt":10,"email":10},"David Birnie, MD, FRCP(C)",{"facility":89,"status":30,"city":90,"state":64,"zip":10,"country":33,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Sunnybrook Hospital","Toronto",{"type":35,"coordinates":92},[93,94],-79.39864,43.70643,{"lat":94,"lon":93},[97,99],{"name":98,"role":20,"phone":10,"phoneExt":10,"email":10},"Ambreen Syeda",{"name":100,"role":16,"phone":10,"phoneExt":10,"email":10},"Eugene Crystal, MD, FRCP(C)",{"facility":102,"status":30,"city":103,"state":104,"zip":10,"country":33,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Montreal Heart Institute","Montreal","Quebec",{"type":35,"coordinates":106},[107,108],-73.58781,45.50884,{"lat":108,"lon":107},[111,113],{"name":112,"role":20,"phone":10,"phoneExt":10,"email":10},"Caroline Girard",{"name":114,"role":16,"phone":10,"phoneExt":10,"email":10},"Lena Rivard, MD, FRCP (C)",{"facility":116,"status":30,"city":117,"state":118,"zip":10,"country":33,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Regina General Hospital","Regina","Saskatchewan",{"type":35,"coordinates":120},[121,122],-104.6178,50.45008,{"lat":122,"lon":121},[125,127],{"name":126,"role":20,"phone":10,"phoneExt":10,"email":10},"Maria Gagarinova",{"name":128,"role":16,"phone":10,"phoneExt":10,"email":10},"Omar Sultan, MD, FRCP(C)",{"type":130,"investigatorFullName":131,"investigatorTitle":132,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Ratika Parkash","Physician",[134],{"name":135,"class":136},"Nova Scotia Health Research Fund","UNKNOWN","100535241",false,"NCT06249269","Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study","RASTA-Cohort","Inclusion Criteria:\n\n* symptomatic AF (CCS-SAF ≥2),\n* paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and either: i) BMI ≥ 30 or, ii) at least two of the following: BMI\\>27, BP\\>140\u002F90 mmHg or history of hypertension, Diabetes, Heart failure (prior heart failure admission or LVEF\\\u003C40%), Age ≥ 65 years, Prior stroke\u002FTIA, Current smoker, Excessive alcohol use {For women: 10 or more drinks\u002Fweek, more than 2 drinks a day (most days). For men: 15 or more drinks\u002Fweek, more than 3 drinks a day (most days)}, and iii) declined or were not approached for participation in the main study. Eligible patients must have received catheter ablation for AF during the same timeline of the RASTA-AF Mian Study (November 1st, 2019 to December 31st, 2025).\n\nExclusion Criteria:\n\n* permanent AF (AF lasting \\> 3 years),\n* prior catheter ablation for AF\n* New York Heart Association Class IV heart failure\n* participation in a cardiac rehabilitation program within the last year,\n* currently performing exercise training \\>150 minutes\u002Fweek of moderate to vigorous physical activity,\n* unable to exercise,\n* unable to give informed consent,\n* other noncardiovascular medical condition making 1 year survival unlikely\n* less than 18 years of age","ALL","18 Years",{"count":146,"type":147},198,"ESTIMATED","2 Years","OBSERVATIONAL","Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It results in high healthcare costs and significant morbidity, especially for patients with severe symptoms. The RASTA-AF randomized control trial (RCT) is designed to answer the following question: does vigorous treatment of AF with aggressive risk factor management plus catheter ablation reduce AF-related outcomes as compared to catheter ablation plus usual care in patients with symptomatic AF and risk factors that promote AF.\n\nThis study is a multicenter, prospective cohort study that will enrol patients who decline participation in the RASTA-AF RCT but agree to be followed in a registry. The objective of RASTA-Cohort is to determine whether patients who decline participation in the RASTA-AF RCT have different clinical characteristics and quality of life than patients who accept participation in the study, and whether they suffer from worse AF-related outcomes than patients in the RCT.",[152],"Atrial Fibrillation, Paroxysmal or Persistent","2025-11-25",{"date":155,"type":156},"2025-12-02","ACTUAL",{"date":158,"type":156},"2024-05-01",{"date":160,"type":147},"2027-03",{"name":131,"class":6},7]